Immunization with human immunodeficiency virus type 1 rgp120W61D in QS21/MPL adjuvant primes T cell proliferation and C-C chemokine production to multiple epitopes within variable and conserved domains of gp120W61D.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

J Infect Dis. 1999 Mar;179(3):558-66. Unique Identifier : AIDSLINE MED/99137790
Jones GJ; von Hoegen P; Weber J; Rees AD; GU Medicine and Communicable Diseases, Imperial College School of; Medicine at St. Mary's, London, W2 1PG, United Kingdom.; gareth.jones@ic.ac.uk

Abstract: Human immunodeficiency virus type 1 (HIV-1) gp120W61D-specific T cell lines (TCL) were generated from an HIV-1-seronegative volunteer who received rgp120W61D in QS21/MPL adjuvant with emulsion. TCL were challenged with pools of consecutive, overlapping peptides spanning the gp120W61D sequence and then with the individual peptides of the immunostimulatory pool. T cell epitopes were found within both variable and conserved domains, and there was no evidence of a single immunodominant epitope. The two most frequently recognized peptides were located in the C1 domain and in the C-terminal region of the V3 loop. Several TCL were shown to recognize multiple peptides from nonoverlapping regions. Peptides from both conserved and variable domains were capable of inducing MIP-1alpha, MIP-1beta, and RANTES production. When tested against the equivalent peptide from the HIV-1IIIB sequence, however, TCL were able to tolerate only minor conserved changes in the amino acid sequence.

Keywords: JOURNAL ARTICLE Amino Acid Sequence Amino Acid Substitution *AIDS Vaccines Cell Line Chemokines, CC/*BIOSYNTHESIS/GENETICS Conserved Sequence CD4-Positive T-Lymphocytes Epitopes/CHEMISTRY/IMMUNOLOGY Human HIV Envelope Protein gp120/CHEMISTRY/GENETICS/*IMMUNOLOGY HIV-1/*IMMUNOLOGY *Lymphocyte Transformation Molecular Sequence Data Mutagenesis, Site-Directed Protein Structure, Secondary Recombinant Proteins/CHEMISTRY/IMMUNOLOGY Support, Non-U.S. Gov't T-Lymphocytes/*IMMUNOLOGY *Vaccines, Synthetic
990630
A9960917

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .